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Abstract
 
The failure of CD25
 
  
 
regulatory T cells (T
 
regs
 
) to proliferate after T cell receptor (TCR) stim-
ulation in vitro has lead to their classification as naturally anergic. Here we use T
 
regs 
 
expressing
a transgenic TCR to show that despite anergy in vitro, T
 
regs 
 
proliferate in response to immuniza-
tion in vivo. T
 
regs 
 
also proliferate and accumulate locally in response to transgenically expressed
tissue antigen whereas their CD25
 
  
 
counterparts are depleted at such sites. Collectively, these
data suggest that the anergic state that characterizes CD25
 
  
 
T
 
regs 
 
in vitro may not accurately re-
flect their responsiveness in vivo. These observations support a model in which T
 
reg 
 
population
dynamics are shaped by the local antigenic environment.
Key words: CD4
 
  
 
T lymphocytes • peripheral tolerance • autoantigen • regulatory T cells • 
autoimmunity
 
Introduction
 
The critical ability of regulatory T cells (T
 
regs
 
)
 
* 
 
to control
diseases, particularly autoimmunity, has sparked much in-
terest in how such cells develop and function. Thymic-
derived CD4
 
  
 
CD25
 
  
 
T cells constitute a major population
of T
 
regs 
 
that are able to inhibit T cell responses both in vitro
(1–3) and in vivo (4, 5). T
 
regs 
 
are widely believed to recog-
nize self-antigens. In fact, the number of CD4
 
  
 
CD25
 
 
 
cells that is selected in the thymus has been shown to be
proportional to the diversity of self-peptides presented in
the context of MHC class II molecules on thymic epithe-
lium (6). Elegant studies using PVG rats have suggested that
T
 
regs 
 
emerging from the thymus require access to their spe-
cific autoantigen in the periphery to survive as a functional
population, and this may reflect a requirement for self-anti-
gen–driven expansion (7). On face value, such a scenario is
hard to reconcile with the profound anergy exhibited by
T
 
regs 
 
in response to TCR engagement in vitro (1, 2, 8).
To study the response of T
 
regs 
 
to antigen in vivo, we have
taken advantage of a murine model that allows the produc-
tion of a large number of CD25
 
  
 
T cells with regulatory
function that bear a transgenic TCR. Using the clonotypic
antibody to identify these cells after adoptive transfer to non-
transgenic recipients, we reveal a key difference between the
responsiveness of T
 
regs 
 
to encounter with antigen in vivo
versus in vitro. The cells are anergic to antigen stimulation
in vitro, but undergo proliferation if presented with immu-
nizing antigen in an in vivo context. Furthermore, after
adoptive transfer of TCR transgenic T
 
regs 
 
to mice transgeni-
cally expressing the relevant antigen (OVA) as a self-protein
in a peripheral tissue, proliferation of a fraction of the T
 
regs
 
can be detected in the lymphoid tissue draining the site of
antigen expression. Although T
 
regs 
 
have been shown to be
capable of homeostatic proliferation in lymphopenic hosts
(9, 10), they are believed to be refractory to antigen-driven
proliferation based on in vitro studies. Our results indicate
that the constraints on antigen-driven T
 
reg 
 
proliferation doc-
umented in vitro are not apparent in vivo and provide new
insight into the biology of this critical T cell subset.
 
Materials and Methods
 
Mice.
 
DO11.10 TCR transgenic mice and BALB/c mice
were purchased from The Jackson Laboratory. RAG2
 
    
 
mice
were purchased from Taconic Laboratories. Rat insulin promoter
(RIP)-mOVA mice on a BALB/c background expressing a
membrane-bound form of OVA under the control of the RIP
(from line 296-1B) were provided by W. Heath (The Walter and
Eliza Hall Institute of Medical Research, Melbourne, Australia).
Mice were housed in the University of California San Francisco
animal facility and used according to the guidelines of the Institu-
tional Committee on Animal Research. Mice were genotyped
using PCR and flow cytometry and were between 6 and 12 wk
of age at the start of each experiment.
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Abbreviations used in this paper
 
: CD40L, CD40 ligand; CFSE, car-
boxy-fluorescein diacetate succinimidyl ester; CTLA-4, cytotoxic T
lymphocyte–associated antigen 4; RIP, rat insulin promoter; T
 
reg
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Antigen-dependent Proliferation of Regulatory T Cells In Vivo
 
T Cell Transfers.
 
Combined LN (axillary, inguinal, brachial,
popliteal, and mesenteric) cells from DO11 
 
  
 
RIP-mOVA dou-
ble transgenic mice (on a RAG
 
    
 
background where indicated)
were stained with the clonotypic antibody KJ-126-APC (Caltag)
and CD25-PE and purified using high speed cell sorting (Mo-
Flo
 
®
 
; DakoCytomation). 0.5–1 
 
  
 
10
 
6 
 
cells were transferred into
recipient mice by tail vein injection. Where indicated, cells were
incubated before transfer with 1 
 
 
 
M carboxy-fluorescein diace-
tate succinimidyl ester (CFSE; Molecular Probes) for 10 min at
room temperature followed by two washes with RPMI supple-
mented as described below. Absolute cell numbers were calcu-
lated based on percentage of CD4
 
  
 
KJ
 
  
 
cells and total cell counts.
Fold expansion is calculated using the average values from unim-
munized mice within each experiment.
 
Immunization.
 
OVA protein (Sigma-Aldrich) was prepared
emulsified in IFA (Difco) and 200 
 
 
 
g was administered s.c. in the
flank where indicated. Axillary and inguinal LNs were taken as
draining LNs and cervical LNs were taken as nondraining LNs.
 
Flow Cytometry.
 
Antibodies used for staining were KJ-126-
biotin/APC, CD25-FITC/PE (PC61), CD62L-FITC (MEL-14),
CD69-PE (H1.2F3), cytotoxic T lymphocyte–associated antigen
4 (CTLA-4)-PE (UC10-4F10-11), CD4-FITC/PERCP (L3T4),
TCR-V
 
 
 
2-PE (B20.1), IL-2-PE (JES6-544), OX40-biotin
(OX-86), streptavidin-PE/PERCP, IL-7R
 
 
 
-PE (SB/14), and
CD40 ligand (CD40L)-PE (MR1). All antibodies were purchased
from BD Biosciences unless otherwise indicated. In some experi-
ments, labeling with CFSE was used to identify adoptively trans-
ferred KJ
 
  
 
CD25
 
  
 
or KJ
 
  
 
CD25
 
  
 
cells from cotransferred re-
sponder DO11 cells. For intracellular cytokine staining, cells were
restimulated for 4 h with 1 
 
 
 
g/ml OVA peptide in the presence
of 10 
 
 
 
g/ml brefeldin A for the final 3 h. Cells were fixed for 10
min with 4% paraformaldehyde after surface staining and then
permeabilized with 0.5% saponin (Sigma-Aldrich) and stained
with antibodies against intracellular markers for 15 min at room
temperature. Stained cells were washed once with 0.5% saponin
and once with 1% FBS in PBS before analysis. Gates were set us-
ing isotype-matched control antibodies.
 
In Vitro Proliferation.
 
2.5 
 
  
 
10
 
4 
 
T cells purified by MoFlo
 
® 
 
sort-
ing were cultured with 1.25 
 
  
 
10
 
5 
 
spleen cells from nontransgenic
mice in 0.2 ml RPMI 1640 supplemented with 1 mM 
 
l
 
-glutamine,
penicillin, streptomycin, nonessential amino acids, sodium pyruvate,
Hepes (all from Life Technologies), 5 
 
  
 
10
 
 
 
5 
 
M 2-ME, and 10%
FBS (Sigma-Aldrich) containing the indicated concentration of
OVA
 
323–339 
 
peptide. For restimulation of draining LN cells, popula-
tions that contained an equivalent percentage of KJ
 
  
 
cells were cul-
tured at a concentration of 5 
 
  
 
10
 
6 
 
total cells per ml in RPMI 1640
supplemented as described above. Proliferation assays were pulsed
with 1 
 
 
 
Ci [
 
3
 
H]thymidine (New England Nuclear) for the final
7–8 h of the 72-h period and incorporated radioactivity was mea-
sured in a Betaplate scintillation counter (LBK Pharmacia).
 
Results
 
Clonotype
 
  
 
CD25
 
  
 
Cells in DO11 
 
  
 
RIP-mOVA Mice.
 
We observed that in double transgenic mice expressing a
membrane-bound form of OVA under the control of the
RIP (RIP-mOVA) and also expressing the DO11 TCR,
there was a large population of clonotype
 
  
 
cells that ex-
pressed CD25 (Fig. 1, A and B). The KJ-126
 
  
 
CD25
 
  
 
cells
(from hereon referred to as KJ
 
  
 
CD25
 
 
 
) were present in
the secondary lymphoid tissues and enriched in the pancre-
atic LN that drains the site of peripheral OVA expression
(Fig. 1 A). Although CD25 is transiently up-regulated dur-
ing T cell activation, the surface expression profile of the
KJ
 
  
 
CD25
 
  
 
cells did not indicate activation because they
were almost exclusively CD62L
 
hi 
 
and did not exhibit ele-
vated levels of CD69 despite expressing high levels of intra-
cellular CTLA-4 when compared with KJ
 
  
 
CD25
 
  
 
cells
from the same mouse (Fig. 1 C). Instead, the phenotype of
the KJ
 
  
 
CD25
 
  
 
cells suggested that they were T
 
regs
 
. The
KJ
 
  
 
CD25
 
  
 
cells expressed higher OX40 and lower IL-7
receptor 
 
  
 
than the KJ
 
  
 
CD25
 
  
 
cells (Fig. 1 C). This is
consistent with microarray analysis of nontransgenic CD4
 
 
 
CD25
 
  
 
cells that showed increased mRNA for OX40 (11)
and decreased mRNA for IL-7 receptor 
 
  
 
(9) compared
with CD4
 
  
 
CD25
 
  
 
cells.
We hypothesized that the KJ
 
  
 
CD25
 
  
 
cells were T
 
regs 
 
that
had arisen as a result of the intrathymic activity of the insulin
promoter (12). Indeed, functionally significant levels of
OVA are expressed in the thymus of RIP-mOVA mice be-
cause the thymic deletion of OT-1 cells in double transgenic
(OT-1 
 
  
 
RIP-mOVA) mice (13) is abolished in thymecto-
mized RIP-mOVA mice grafted with a nontransgenic thy-
mus and OT-1 bone marrow (14). Consistent with a thymic
origin, KJ
 
  
 
CD25
 
  
 
cells were present in the CD4
 
  
 
CD8
 
 
 
fraction of thymocytes from DO11 
 
  
 
RIP-mOVA mice
(Fig. 1, A and B). The total number of DO11 T cells in the
thymus in DO11 
 
  
 
RIP-mOVA double transgenic mice
was reduced compared with single positive DO11 mice
(7.5 
 
  
 
2.4 
 
  
 
10
 
6 
 
compared with 21.5 
 
  
 
5.9 
 
  
 
10
 
6
 
, respec-
tively), suggesting that thymic OVA expression also induced
negative selection of a proportion of the clonotype
 
  
 
cells.
The KJ
 
  
 
CD25
 
  
 
cells were not enriched for cells express-
ing endogenous TCR
 
  
 
chains because the proportion of
cells expressing V
 
 
 
2 (an endogenous TCR
 
  
 
chain) was
slightly lower in the KJ
 
  
 
CD25
 
  
 
population than in the KJ
 
 
 
CD25  population (Fig. 2 A). Levels of the transgenic TCR
were equivalent between KJ  CD25  cells and KJ  CD25 
cells as assessed by KJ-126 staining (Fig. 2 A). The lack of
increased endogenous TCR  chain usage argued against a
requirement for the rearrangement of additional TCRs for
the development of the KJ  CD25  cells. Consistent with
this, the development of KJ  CD25  cells was intact in
DO11   RIP-mOVA mice bred to a RAG-deficient back-
ground (Fig. 2 B). In line with previous reports (15), the
small number of CD25  cells that develop in conventional
DO11 mice require endogenous TCR  chains and do not
arise in DO11 RAG /  mice (Fig. 2 B). Thymic deletion
of DO11 cells was also evident in the DO11    RIP-
mOVA RAG    mice (8.7   5.2   106 KJ  CD4  CD8 
cells in the thymus of DO11   RIP-mOVA RAG    mice
compared with 20.7   6.7   106 in DO11 RAG    mice).
Therefore, both deletion and Treg differentiation of DO11
cells were evident in antigen-bearing mice in a manner that
was independent of endogenous TCR  chain usage.
KJ  CD25  Cells Suppress T Cell Responses In Vitro and In
Vivo. To confirm that the KJ  CD25  cells were Tregs we
analyzed their suppressive function in vitro. For these ex-T
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periments, we sorted highly pure populations of KJ 
CD25  and KJ  CD25  cells from pooled peripheral LNs
of DO11    RIP-mOVA double transgenic mice. KJ 
CD25  cells did not proliferate in response to OVA323–339
peptide and APCs, whereas KJ  CD25  cells purified from
the same mice showed a robust proliferative response (Fig.
3 A). Furthermore, in cocultures, KJ  CD25  cells potently
suppressed the proliferation of KJ  CD25  cells (Fig. 3 A).
KJ  CD25  cells isolated from DO11   RIP-mOVA mice
appeared to suppress with equivalent potency to the much
less abundant KJ  CD25  cells isolated from conventional
DO11 mice (suppression observed at 0.1  g/ml OVA us-
ing a 1:1 ratio of suppressors/responders was 96 versus
93%, respectively, and using a ratio of 0.5:1 was 69 versus
74%, respectively). KJ  CD25  cells from conventional
DO11 mice can presumably still be induced to suppress via
their transgenic TCR despite undergoing thymic selection
on the basis of an alternative TCR.
One advantage of using a TCR transgenic system to
study Treg function is the ability to perform in vivo experi-
ments in which “responder” and “suppressor” T cells of
the same specificity can be adoptively transferred into non-
transgenic hosts and tracked using the clonotypic antibody
KJ-126. We were therefore able to assess whether KJ 
CD25  cells were capable of suppressing the response of
naive DO11 cells to OVA emulsified in IFA. To distin-
guish between the two populations, we used CFSE labeling
to mark the suppressor cells (KJ  CD25  cells or control
transfers of KJ  CD25  cells). Fig. 3 B shows that the accu-
mulation of responder (CFSE ) DO11 cells in response to
immunization was decreased if CFSE-labeled KJ  CD25 
cells were cotransferred before immunization. Control
transfers of CFSE-labeled KJ  CD25  cells did not decrease
the accumulation of DO11 cells after immunization, indi-
cating that the inhibition observed with KJ  CD25  cells
was not simply a consequence of competition for peptide.
No accumulation of DO11 cells was observed in nondrain-
ing LNs in response to immunization (not depicted).
KJ  CD25  Cells Proliferate in Response to Immuniza-
tion. During the course of these experiments, we made
the unexpected observation that the KJ  CD25  cells ap-
peared to divide after immunization as assessed by loss of
CFSE dye. To characterize directly the response of KJ 
CD25  cells to encounter with antigen in vivo, we adop-
Figure 1. Abundant clonotype  CD25  cells in DO11   RIP-mOVA double transgenic
mice. (A) FACS® profiles of DO11 single positive versus DO11   RIP-mOVA double trans-
genic littermates at 7 wk of age. Cells were isolated from the indicated lymphoid tissues and
stained with CD4-PERCP, CD25-PE, and KJ-126-APC. Plots are gated on CD4  KJ  cells
(except for thymus plots, which are gated on CD4  CD8  KJ  cells) and show the percentage of
CD25  cells. (B) Absolute number of CD4  KJ  CD25  cells in the lymphoid tissues of DO11
single positive versus DO11   RIP-mOVA double transgenic littermates. Data show mean and standard deviation from three mice of each genotype
aged 6–7 wk. (C) Peripheral LN cells from DO11   RIP-mOVA double transgenic mice were stained with various combinations of KJ-126-APC,
CD62L-FITC, CD69PE, CD4-PERCP, OX40- biotin, streptavidin-PE, IL-7R -PE, and CD25-FITC/PE. For intracellular staining cells were surface
stained and then permeabilized and stained with CTLA-4-PE. Expression profiles of each marker are shown for gated CD4  KJ  CD25  versus CD4 
KJ  CD25  cells.T
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tively transferred CFSE-labeled KJ  CD25  or KJ  CD25 
cells into BALB/c recipients immunized with OVA protein
in IFA, and examined the CFSE profiles of the KJ  cells iso-
lated from the draining LNs 3, 6, or 8 d later. As expected,
KJ  CD25  cells showed a strong proliferative response to
immunization (Fig. 4 A). Strikingly, despite being anergic
to stimulation in vitro (Fig. 3 A), the adoptively transferred
KJ  CD25  cells proliferated in response to immunization
in vivo (Fig. 4 A). KJ  CD25  and KJ  CD25  cells isolated
from nondraining LNs remained largely CFSE high (Fig. 4
A, day 3 data shown). Table I shows the percentage of KJ 
cells that were CFSE low, the median fluorescence channel
of the divided fraction, and the absolute number of KJ  cells
for each of the conditions shown in Fig. 4 A.
The absolute number of KJ  CD25  cells in the draining
LNs increased in response to immunization (Fig. 4 B). The
fold expansion observed in the recipients of KJ  CD25 
cells 3 d after immunization in the experiments shown in
Fig. 4 B (3.9-, 2.7-, 2.5-, and 2.1-fold) was similar to that
observed for the KJ  CD25  cells (3.5-, 2.6-, and 3.0-fold).
Strikingly, when draining LN cells were isolated from re-
cipient mice 3 d after immunization and subjected to re-
stimulation in vitro, LN cells from recipients of KJ 
CD25  cells showed a strong proliferative response to
Figure 2. The generation of
KJ   CD25   cells does not re-
quire endogenous TCR  chains.
(A) Frequency of TCR V 2 us-
age and expression levels of the
transgenic TCR on peripheral
LN cells from DO11    RIP-
mOVA mice. Histogram labels
depict the median fluorescence
channel. (B) Proportion of
CD4  KJ  cells expressing CD25
in DO11 versus DO11   RIP-
mOVA mice on a RAG   
background. Cells were isolated
and stained as described in Fig. 1.
Figure 3. KJ  CD25  cells are suppressive in vitro and in vivo. (A)
KJ  CD25  and KJ  CD25  populations were purified from pooled pe-
ripheral LNs of DO11   RIP-mOVA double transgenic mice by high
speed cell sorting and stimulated in 96-well plates, either alone or in
combination at a 1:1 ratio, with BALB/c splenocytes and the indicated
concentration of OVA323–339 peptide. Data show one experiment that is
representative of three. (B) 2   106 DO11 T cells (from a single positive
DO11 mouse) were injected into BALB/c recipients either alone or in
combination with 106 CFSE-labeled KJ  CD25  cells or 106 CFSE-
labeled KJ  CD25  cells. Recipient mice were immunized s.c. with 200
 g OVA/IFA where indicated. Draining LNs were isolated at day 3 and
the absolute number of responder DO11 cells (CFSE ) is shown. Data
show one experiment (two mice per group) and are representative of two
separate experiments.T
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OVA323–339 peptide whereas LN cells from recipients of
KJ  CD25  cells did not proliferate (Fig. 4 C). The per-
centage of KJ  cells in the starting populations isolated from
recipient mice was equivalent in both cases (0.08 and
0.06% for recipients of KJ  CD25  cells and 0.08 and
0.05% for recipients of KJ  CD25  cells in the experiment
shown in Fig. 4 C). Collectively, these data suggest that al-
though Tregs are anergic to simulation in vitro, they are able
Figure 4. KJ  CD25  cells prolifer-
ate in vivo in response to immunization.
0.5   106 CFSE-labeled KJ  CD25  or
KJ  CD25  cells were adoptively trans-
ferred into BALB/c recipients that were
immunized s.c. 24 h later with 200  g
OVA/IFA where indicated. Draining
and nondraining LNs were isolated at
the indicating time points after immuni-
zation and a fraction were stained with
KJ-126-APC, CD4-PERCP, and
CD25-PE whereas the rest were re-
served for restimulation. (A) CFSE pro-
file of gated CD4  KJ  cells harvested at
the indicated time points after immuni-
zation. (B) Absolute number of CD4 
KJ  cells at day 3 after immunization
(symbols depict separate experiments).
(C) Draining LN cells from two recipi-
ents of KJ  CD25  cells and two recipi-
ents of KJ  CD25  cells were isolated
3 d after immunization and restimulated
in vitro with OVA323–339 peptide. Prolif-
eration was assessed 72 h later. Similar
data were obtained in three independent
experiments. (D) KJ  CD25  cells were
sorted from conventional DO11 mice,
CFSE labeled, and 106 cells were adop-
tively transferred into BALB/c recipients
that were immunized where indicated
24 h later as described above. CFSE
profiles of gated CD4  KJ  cells 3 d after
immunization are shown.
Table I. Proliferation of KJ  CD25  and KJ  CD25  Cells in Response to Immunization
Percent M2 (CFSE low) Median fluorescence channel (within M2) Number KJ  cells ( 10-3)
KJ  CD25 
No immunization (day 3) 6.34 37.8 6.32
Day 3 after immunization 71.34 54.25 22.5
Day 6 after immunization 85.8 59.64 93.0
Day 8 after immunization 98.56 33.76 111.36
Nondraining LN (day 3) 11.73 32.78 1.64
KJ  CD25 
No immunization (day 3) 2.54 39.24 4.35
Day 3 after immunization 63.21 77.74 12.7
Day 6 after immunization 89.52 99.65 31.0
Day 8 after immunization 93.63 87.32 39.9
Nondraining LN (day 3) 10.36 42.17 2.05
The data depicted in Fig. 4 A were quantitated in terms of the percentage of KJ  cells that were CFSE low, the median fluorescence channel within
the divided population, and the absolute number of CD4  KJ  cells at each time point.T
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to proliferate in response to antigen in vivo. The observa-
tions made using KJ  CD25  cells from DO11   RIP-
mOVA mice were confirmed using the much rarer KJ 
CD25  cells isolated from conventional DO11 mice that
also proliferated in response to immunization (Fig. 4 D).
Antigen-driven proliferation did not block the ability of
Tregs to suppress immune responses because the KJ  CD25 
cells could suppress T cell responses under the same condi-
tions that induced their own proliferation (Fig. 3 B).
Defective IL-2 Induction in KJ  CD25  Cells. To assess
whether the proliferation of KJ  CD25  cells reflected an
equivalent program of activation to that exhibited by the
KJ  CD25  cells, we examined cytokine expression by in-
tracellular staining. Although the KJ  CD25  cells entered
cell cycle, there was a striking lack of IL-2 production in
these cells compared with the KJ  CD25  cells at all the time
points examined (Fig. 5 A). It is intriguing to speculate that
this might be associated with the preferential expression of
the transcription factor Foxp3 in CD25  Tregs (16, 17) that
has been shown to inhibit transcription of IL-2 in a Jurkat
transfection system (18). At day 3 after immunization, a pro-
portion of the KJ  CD25  cells produced IFN   and a
smaller fraction stained positive for IL-4 (Fig. 5 B). How-
ever, neither of these effector cytokines could be detected in
KJ  CD25  cells responding to immunization (Fig. 5 B). We
were also unable to detect IL-10 protein in the KJ  CD25 
cells either before or after immunization (Fig. 5 B and un-
published data). In addition to supplying cytokines, helper T
cells can also modulate immune responses by the activation-
induced provision of CD40L. To assess the capacity of
CD25  Tregs to fulfill this function, we examined CD40L ex-
pression in the KJ  CD25  cells responding to immuniza-
tion. Levels of CD40L were greatly reduced in KJ  CD25 
cells compared with KJ  CD25  cells. Collectively, these
data suggest that CD25  Tregs make a qualitatively different
response to immunization compared with CD25  cells.
Response of KJ  CD25  Cells to Tissue-expressed Anti-
gen. The observation that KJ  CD25  cells could prolifer-
ate in response to immunogenic antigen raised the intrigu-
ing possibility that Tregs are not anergic in vivo but instead
might be capable of responding to the self-antigens that
they recognize. To address this possibility, we examined
the response of KJ  CD25  cells to OVA expressed trans-
genically as a self-antigen on pancreatic   cells. It has previ-
ously been shown that naive CD4 T cells specific for a
pancreas-expressed protein undergo proliferation in the
Figure 5. Cytokine profiles of KJ  CD25  cells responding to immunization. 0.5   106 CFSE-labeled KJ  CD25  or KJ  CD25  cells were adoptively
transferred into BALB/c recipients that were immunized s.c. 24 h later with 200  g OVA/IFA. Draining LNs were isolated at the indicated time point
after immunization, restimulated for 4 h with 1  g/ml OVA323–339 peptide, fixed, permeabilized, and stained for intracellular proteins as described in Ma-
terials and Methods. Plots are gated on CD4  KJ  cells. (A) Kinetic analysis of IL-2 induction in response to immunization. (B) Analysis of IFN , IL-4,
IL-10, and CD40L at day 3 after immunization. For IL-10 detection, CD4 was detected with PERCP rather than FITC accounting for the slightly lower
fluorescence observed. Data are representative of at least three independent experiments.T
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pancreatic LN (19–21). We therefore compared the prolif-
erative response of CFSE-labeled KJ  CD25  cells with
that of CFSE-labeled KJ  CD25  cells after adoptive trans-
fer into mice bearing the cognate antigen, OVA, in the
pancreas. 6 d after adoptive transfer to RIP-mOVA mice, a
proportion of the KJ  CD25  had undergone proliferation
in response to tissue-derived antigen as judged by loss of
CFSE dye (Fig. 6 A). The proliferation of KJ  CD25  cells
was less marked than that of KJ  CD25  cells. However,
the CFSE profiles suggested that a small fraction of KJ 
CD25  cells had entered cell cycle in the pancreatic LN in
a manner that was not observed in nondraining LNs iso-
lated from the same mice (Fig. 6, A and B). KJ  CD25  or
KJ  CD25  cells adoptively transferred into nontransgenic
recipients did not proliferate in either the inguinal LN or
pancreatic LN (not depicted).
Reciprocal Homeostasis of KJ  CD25  and KJ  CD25 
Cells Proliferation of CD25  T cells in response to tissue-
derived antigen is not associated with an increase in cell
number. In fact, we have previously noted that the number
of DO11 cells decreases after transfer to RIP-mOVA
mice compared with nontransgenic recipients (unpublished
data). This phenomenon has also been observed for CD8 T
cells and is consistent with the induction of apoptosis in the
cells responding to tissue antigen (14). To directly compare
the effect of encounter with tissue antigen on KJ  CD25 
cells versus KJ  CD25  cells, we adoptively transferred pu-
rified populations into either RIP-mOVA mice or their
transgene-negative littermates and assessed the absolute
number of KJ  cells in the pancreatic LNs 8 d later. As we
have previously observed, the number of KJ  CD25  cells
recovered from the pancreatic LNs of RIP-mOVA mice
was lower than that recovered from nontransgenic hosts
(Fig. 7 A). The number of KJ  CD25  cells recovered from
the LNs of nontransgenic mice tended to be lower than
that of KJ  CD25  cells, likely reflecting the hyporespon-
siveness of Tregs to lymphoid chemokines that may limit
their ability to enter lymphoid tissues (9). Despite this, the
number of KJ  CD25  cells recovered from the pancreatic
LN of RIP-mOVA recipients was higher than that recov-
ered from transgene-negative littermates (Fig. 7 A). In line
with preferential accumulation at the site of self-antigen,
the percentage of KJ  CD25  cells in pancreatic LNs was
Figure 6. Proliferative response of KJ  CD25  and KJ  CD25  cells to
tissue-expressed antigen. 106 CFSE-labeled KJ  CD25  or KJ  CD25 
cells were adoptively transferred into RIP-mOVA recipients. 6 d later
pancreatic LNs and inguinal LNs were isolated from recipient mice and
stained with KJ-126-APC, CD4-PERCP, and CD25-PE. (A) CFSE pro-
files of gated CD4  KJ  cells in one experiment. MFI shows the median
fluorescence channel for the CFSE low fraction. (B) Percentage of CD4 
KJ  cells that were CFSE low in four separate experiments.
Figure 7. Differential regulation of KJ  CD25  and KJ  CD25  cell
numbers in response to self-antigen. 0.5   106 KJ  CD25 , KJ  CD25 
RAG   , KJ  CD25 , or KJ  CD25  RAG    cells were adoptively trans-
ferred into RIP-mOVA recipients or their transgene-negative littermates.
8 d later recipient mice were killed and pancreatic LN cells and inguinal
LN cells were stained with KJ-126-APC, CD4-PERCP, and CD25-PE.
(A) Absolute number of CD4  KJ  cells in the pancreatic LNs of RIP-
mOVA or transgene-negative recipients. (B) Percentage of KJ   cells
(within the CD4  population) in the pancreatic LNs and inguinal LNs of
RIP-mOVA recipients. Lines join data points from the same experiment.T
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consistently greater than that seen in nondraining nodes
within the RIP-mOVA recipients (Fig. 7 B). When the re-
arrangement of additional TCR specificities in the KJ  cells
was precluded by RAG deficiency, the same trends were
observed both at day 8 (Fig. 7, A and B) and day 14 (un-
published data). Collectively, these experiments indicate
that CD25  and CD25  cells bearing the same antigen
specificity respond differentially to encounter with antigen
draining from a peripheral tissue. CD25  cells proliferate
yet ultimately decrease in number, consistent with the in-
duction of apoptosis. In contrast, CD25  cells show a small
proliferative response to tissue antigen and their representa-
tion is increased locally, both proportionally and in terms of
absolute cell number.
Discussion
In vitro characterization of CD4  CD25  Tregs has led to
the view that this subset constitutes a “naturally anergic”
population (1, 15). In fact, treatments that break Treg an-
ergy, such as the addition of exogenous IL-2 to cultures,
tend to abrogate the ability of Tregs to suppress (2, 8). The
diverse antigen specificity of naturally occurring CD4 
CD25  cells has so far precluded study of the impact of an-
tigen receptor signaling on peripheral Treg responses in
vivo. We have circumvented this problem by using Tregs
whose specificity is dictated by a transgenic TCR. Al-
though refractory to stimulation in vitro, we demonstrate
that Tregs proliferate in vivo in response to immunization
and this does not abrogate their ability to suppress CD25 
T cells. Although the number of Tregs that enter cell cycle is
similar to that seen in the control population of TCR
transgenic CD25  cells, the qualitative aspects of the re-
sponse are markedly different as exemplified by defective
induction of IL-2, effector cytokines, and CD40L in the
Tregs. Thus, despite proliferation, Tregs do not adopt a phe-
notype consistent with the provision of T cell help to CD8
cells or B cells.
The proliferation of Tregs in vivo was somewhat surpris-
ing given their nonresponsiveness in vitro. However, Tregs
are known to be highly sensitive to TCR signaling and can
be induced to exert inhibition at peptide concentrations up
to 100-fold lower than those required for the proliferation
of CD25  cells (1). Furthermore, the finding that CD4 
CD25  cells exhibit robust MHC class II–dependent pro-
liferation in lymphopenic recipients (9, 10) suggests that
their TCR is clearly capable of transmitting a proliferative
signal. The reversion to an anergic phenotype upon re-
moval of Tregs to an in vitro setting in the former study is
intriguingly similar to the findings reported here. One pos-
sibility is that the apparently anergic phenotype of Tregs in
vitro might be a feature of the high cell density in culture
that allows inhibition by cell–cell contact in a manner that
does not occur within secondary lymphoid tissues. Alterna-
tively, Tregs stimulated in culture may secrete inhibitory cy-
tokines that accumulate and suppress their proliferation.
Another plausible explanation for the differential respon-
siveness observed in this study is that additional growth fac-
tors are available in vivo to support Treg proliferation and
that these are lacking in minimalist in vitro setups.
There is some evidence to suggest that CD25  Tregs iso-
lated from different anatomical sites are not functionally
equivalent. In an inflammation-induced diabetes model,
Tregs had to be derived from the pancreatic LN to exert dis-
ease protection (22). We were therefore interested in the
ability of the KJ  CD25  cells used in our study to respond
to their local antigenic environment. Intriguingly, adoptive
transfers into RIP-mOVA recipients suggested that CD25 
and CD25  cells might be inversely regulated after en-
counter with tissue-derived antigen. The antigen-specific
CD25  cells underwent a reduction in absolute cell num-
bers in the pancreatic LN, likely reflecting the local induc-
tion of apoptosis as has been demonstrated for both CD8
and CD4 T cells after encounter with tissue-derived anti-
gen (14, 23, 24). Conversely, the antigen-specific CD25 
population showed a net increase in cell number in the
pancreatic LNs of antigen-bearing recipients compared
with transgene-negative littermates. This may reflect the
more modest proliferative response that fails to prime the
cells for apoptosis. There is some precedent for a decreased
susceptibility of Tregs to apoptosis in vivo (25), although
these observations relate to Fas-dependent activation-
induced cell death rather than the BIM-dependent path-
way that is believed to mediate death in response to tissue-
derived antigen (26). An alternative mechanism that may
contribute to the increased number of CD25  antigen-spe-
cific T cells at sites draining peripheral antigen expression is
increased recruitment from the circulation. Intriguingly,
the Tregs in this study exhibited relatively poor accumula-
tion in lymphoid tissues in the absence of antigen com-
pared with their CD25  counterparts (Fig. 4 B, unimmu-
nized controls and Fig. 7, transgene-negative littermates),
in line with previous observations by others (9). Exposure
to antigen could provide Tregs with crucial cues for recruit-
ment to or retention in lymphoid organs or peripheral tis-
sues. The accumulation of CD25  cells at the site of long-
term pathogen retention in a recent study suggests that this
paradigm could hold true for foreign as well as self-antigens
(27). Regardless of the underlying mechanisms, the net ef-
fect of encounter with tissue-derived antigen in our study is
to reciprocally regulate CD25  and CD25  T cells num-
bers. Thus, encounter with self-antigen may positively reg-
ulate Treg homeostasis while negatively regulating the ho-
meostasis of potentially pathogenic self-reactive T cells.
We were initially surprised that the expression of a trans-
gene in a peripheral tissue appeared to drive Treg develop-
ment in the thymus. However, mounting evidence sug-
gests that so-called “tissue-specific” promoters, including
that of the insulin gene, are in fact active in the thymus (12,
28). Indeed, insulin protein can be detected in medullary
thymic epithelial cells (28) and its expression appears to be
dependent on the activity of the transcription factor AIRE
(29). Thus, T cells maturing in the thymus have the poten-
tial to interact with proteins whose expression is otherwise
restricted to specific organs. Such interactions could medi-
ate Treg development in addition to facilitating negative se-T
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lection of immature T cells. Consistent with negative selec-
tion and Treg  differentiation occurring in parallel, the
absolute number of DO11 cells was decreased in the thy-
mus of DO11   RIP-mOVA mice compared with single
transgenic DO11 mice. This mirrors the simultaneous neg-
ative selection and Treg development observed in double
transgenic mice bearing the DO11 TCR and OVA ex-
pressed systemically in nuclei (30). Mechanistically, how-
ever, negative selection and Treg development can be un-
coupled because transgenic T cells that bind antigen with
sufficient affinity to mediate deletion do not necessarily ex-
hibit Treg differentiation (31).
It has previously been shown that although antigen ex-
pression on thymic epithelium favors the development of
CD25  Tregs (31), expression of antigen by hematopoietic
cells in the periphery can induce Tregs that are CD25  (32).
The finding that the KJ  CD25  cells, but not the KJ 
CD25  cells, were suppressive in DO11   RIP-mOVA
mice is consistent with a model in which OVA expression
in the thymus favors CD25  Treg development, whereas the
relative paucity of antigen in the periphery fails to induce
CD25  Tregs. In contrast, in models where peripheral anti-
gen is more widely expressed, for example where hemag-
glutinin is expressed under the control of the immunoglob-
ulin   promoter, the CD25  antigen-specific T cells are
also anergic and suppressive (32). It will be of future inter-
est to determine whether the same rules govern the antigen
responsiveness and peripheral homeostasis of both CD25 
and CD25  Treg subsets. In addition, there is evidence that
a distinct, yet phenotypically similar, population of CD25 
Tregs can be induced in the periphery after administration of
intravenous or oral antigen (33). How closely the antigen
responsiveness of these cells in vivo resembles that of thy-
mic-derived CD25  Tregs remains to be tested.
In conclusion, we have used Tregs bearing a transgenic
TCR to enable us to examine their response to antigen in
vivo. Tregs are known to be costimulation dependent (34),
but the role of antigen in their peripheral homeostasis has
not previously been addressed. The surprising ability of
Tregs to proliferate in response to antigen in vivo offers a
new perspective on the behavior of these cells within a
physiological setting. Rather than constituting an anergic
population, our results favor a model in which Tregs re-
spond dynamically to their local antigenic environment.
The ability to proliferate and accumulate after TCR en-
gagement implies that local homeostatic mechanisms may
serve to shape the repertoire of available Tregs at any given
site.
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